您好,欢迎来到上海士研管理咨询有限公司
士研峰会 士研智库 士研调研
嘉宾信息
沈孝坤
沈孝坤
所属职位: CEO
所属公司:

甫康(上海)健康科技有限公司

沈孝坤博士,甫康药业公司CEO,毕业于武汉大学医学院获得临床医学和生物科学双学位,在中科院上海药物研究所获药理学博士学位。先后在恒瑞、诺华等国内外的知名企业从事过小分子和抗体新药研发,有10多年新药研发经验,主导和参与过抗肿瘤、免疫、皮肤等多种疾病领域新药的临床开发,并且帮助多个药物成功国内上市,其中包括First-In-Class的IL-17 抗体苏金单抗(Cosentyx)等。
甫康药业公司是一家处于临床阶段的生物医药公司,研发具备“First-In-Class”和“Best-in-Class”潜力的新疗法,具备强大的新药研发与临床开发能力,立足中国,面向全球。

Dr. Shen Xiaokun, CEO of Convalife Pharmaceutical Co., Ltd., graduated from Wuhan University with degrees in clinical medicine and Bioscience, and obtained Ph.D degree in pharmacology from Shanghai Institute of Materia Medica, CAS. Dr. Shen has been engaged in the research and development of new drugs for small molecules and antibodies in Hengrui, Novartis and other well-known enterprises. Dr. Shen has more than 10 years of experience in the research and development of new drugs. He has led and participated ~10 projects in the clinical development of new drugs in the fields of anti-tumor, immunity, dermatology and other diseases. He has also helped several drugs to be successfully NDA in China, including first in class IL-17 antibody, Cosentyx, etc.
Convalife originated from Latin “valere”, meaning “value and strong”
Convalife is an innovative, research-based, clinical stage biopharmaceutical company focused on bringing innovative therapies for cancer, autoimmune and infectious diseases to patients in China and around the world. Convalife develops new therapies with the potential of 'first in class' and 'best in class', and has strong new drug R & D and clinical development capabilities. Convalife obtained investment of famous listed companies such as Wuxibiologics (HK. 02269), Menovo Pharmaceutical (603538) etc.

微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务